SBRI Healthcare Launches New Competitions, with £5 Million to Invest this Year
SBRI Healthcare, an NHS England funded initiative to develop innovative products and services that address unmet health needs, has announced a it will distribute £5 million of government investment to support small business this year.
The Small Business Research Initiative (SBRI) healthcare competitions provide seed funding for the development of novel solutions to major healthcare challenges. In this new round of competitions, SBRI Healthcare will be looking for companies specifically focused on driving towards better health outcomes for patients across seven categories; cancer, cardiovascular, COPD, diabetes, mental health/dementia, patient safety and research tools.
The Prime Minister’s UK Strategy for Health Innovation and Life Sciences — Innovation, Health and Wealth* (IHW) — set the approach for innovation in the reformed NHS, making a commitment to double investment in the SBRI programme to address healthcare challenges, encourage greater competition in procurement of services and drive growth in the UK Small and Medium size Enterprises (SME) sector.
Investing £17.6 million to date in support of 66 SMEs, the further £5 million in funding is recognition of the value small businesses bring to the NHS to help them deliver new technologies to patients and for these to be adopted widely across the NHS.
Miles Ayling, Director of Innovation, NHS England said: “Innovation Health and Wealth set out the agenda to spread best practice across the NHS whilst at the same time supporting economic growth and wealth creation. The Small Business Research Initiative is a way for NHS England to generate a pipeline of new ideas and technologies with predominantly small to medium sized companies. The ideas in this sector are often highly innovative and exciting — bringing a step change to the way the NHS can deliver quality care for patients. In Innovation Health and Wealth the NHS set out to double the investment in SBRI — NHS England has already committed £5 million this year and today’s competition launch will support industry with a further £5 million investment.”
Sir Mike Rawlins, Chair of the Eastern Academic Health Science Network (EAHSN), who lead the programme on behalf of NHS England commented: “The NHS is a great market place for new technology companies. Through the SBRI programme we can find new ways of solving old problems, which benefit patients and support business growth. In the NHS we have world leading clinical expertise and through programmes such as SBRI Healthcare we can work with business experts to maximise the benefit to the NHS and the economy.”
Peter Ellingworth OBE, Chair of the SBRI Management Board and Chief Executive of the Association of British Healthcare Industries welcomed the new competition: “The med tech industry is an important success story for the UK economy. Many companies already work closely with the NHS but the SBRI programme supports new partnerships to develop and succeed. Through SBRI the companies can gain funding but also the expert support of the NHS to develop products that are truly reflecting NHS need. I hope many companies take a good look and apply for this programme.”
The competition theme areas have been chosen in partnership with the newly designated Academic Health Science Networks (AHSNs) across England. The programme management is led by the Eastern Academic Health Science Network (EAHSN) on behalf of NHS England and other AHSNs. Health Enterprise East is the management partner and supports the EAHSN to handle the applications, assessments and delivery against contracts.
Briefing events for business to learn about the competition will take place on the 24 September (Nottingham), 30 September (London) and 2 October (Manchester) 2013. To find out more visit www.sbrihealthcare.co.uk
* published in December 2011
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance